131 related articles for article (PubMed ID: 38845188)
1. Generation and Characterization of Novel Pan-Cancer Anti-uPAR Fluorescent Nanobodies as Tools for Image-Guided Surgery.
Mateusiak Ł; Floru S; De Groof TWM; Wouters J; Declerck NB; Debie P; Janssen S; Zeven K; Puttemans J; Vincke C; Breckpot K; Devoogdt N; Hernot S
Adv Sci (Weinh); 2024 Jun; ():e2400700. PubMed ID: 38845188
[TBL] [Abstract][Full Text] [Related]
2. Side-by-Side Comparison of uPAR-Targeting Optical Imaging Antibodies and Antibody Fragments for Fluorescence-Guided Surgery of Solid Tumors.
Baart VM; van Manen L; Bhairosingh SS; Vuijk FA; Iamele L; de Jonge H; Scotti C; Resnati M; Cordfunke RA; Kuppen PJK; Mazar AP; Burggraaf J; Vahrmeijer AL; Sier CFM
Mol Imaging Biol; 2023 Feb; 25(1):122-132. PubMed ID: 34642899
[TBL] [Abstract][Full Text] [Related]
3. uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: proof-of-concept in orthotopic xenograft model.
Christensen A; Juhl K; Persson M; Charabi BW; Mortensen J; Kiss K; Lelkaitis G; Rubek N; von Buchwald C; Kjær A
Oncotarget; 2017 Feb; 8(9):15407-15419. PubMed ID: 28039488
[TBL] [Abstract][Full Text] [Related]
4. IRDye800CW labeled uPAR-targeting peptide for fluorescence-guided glioblastoma surgery: Preclinical studies in orthotopic xenografts.
Kurbegovic S; Juhl K; Sørensen KK; Leth J; Willemoe GL; Christensen A; Adams Y; Jensen AR; von Buchwald C; Skjøth-Rasmussen J; Ploug M; Jensen KJ; Kjaer A
Theranostics; 2021; 11(15):7159-7174. PubMed ID: 34158842
[TBL] [Abstract][Full Text] [Related]
5. Molecular Targeted NIR-II Probe for Image-Guided Brain Tumor Surgery.
Kurbegovic S; Juhl K; Chen H; Qu C; Ding B; Leth JM; Drzewiecki KT; Kjaer A; Cheng Z
Bioconjug Chem; 2018 Nov; 29(11):3833-3840. PubMed ID: 30296054
[TBL] [Abstract][Full Text] [Related]
6. A multimodal molecular imaging approach targeting urokinase plasminogen activator receptor for the diagnosis, resection and surveillance of urothelial cell carcinoma.
Baart VM; van der Horst G; Deken MM; Bhairosingh SS; Schomann T; Sier VQ; van der Mark MH; Iamele L; de Jonge H; Resnati M; Mazar AP; Pelger RCM; van der Pluijm G; Kuppen PJK; Vahrmeijer AL; Sier CFM
Eur J Cancer; 2021 Mar; 146():11-20. PubMed ID: 33561783
[TBL] [Abstract][Full Text] [Related]
7. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and characterization of an (111)In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR).
Liu D; Overbey D; Watkinson L; Giblin MF
Bioconjug Chem; 2009 May; 20(5):888-94. PubMed ID: 19354275
[TBL] [Abstract][Full Text] [Related]
9. uPAR-targeted optical imaging contrasts as theranostic agents for tumor margin detection.
Yang L; Sajja HK; Cao Z; Qian W; Bender L; Marcus AI; Lipowska M; Wood WC; Wang YA
Theranostics; 2013; 4(1):106-18. PubMed ID: 24396518
[TBL] [Abstract][Full Text] [Related]
10. Peptide-Based Optical uPAR Imaging for Surgery: In Vivo Testing of ICG-Glu-Glu-AE105.
Juhl K; Christensen A; Persson M; Ploug M; Kjaer A
PLoS One; 2016; 11(2):e0147428. PubMed ID: 26828431
[TBL] [Abstract][Full Text] [Related]
11. Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours.
Debie P; Lafont C; Defrise M; Hansen I; van Willigen DM; van Leeuwen FWB; Gijsbers R; D'Huyvetter M; Devoogdt N; Lahoutte T; Mollard P; Hernot S
J Control Release; 2020 Jan; 317():34-42. PubMed ID: 31734445
[TBL] [Abstract][Full Text] [Related]
12. uPAR-targeted multimodal tracer for pre- and intraoperative imaging in cancer surgery.
Boonstra MC; van Driel PB; van Willigen DM; Stammes MA; Prevoo HA; Tummers QR; Mazar AP; Beekman FJ; Kuppen PJ; van de Velde CJ; Löwik CW; Frangioni JV; van Leeuwen FW; Sier CF; Vahrmeijer AL
Oncotarget; 2015 Jun; 6(16):14260-73. PubMed ID: 25895028
[TBL] [Abstract][Full Text] [Related]
13. Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma.
Persson M; Nedergaard MK; Brandt-Larsen M; Skovgaard D; Jørgensen JT; Michaelsen SR; Madsen J; Lassen U; Poulsen HS; Kjaer A
J Nucl Med; 2016 Feb; 57(2):272-8. PubMed ID: 26429955
[TBL] [Abstract][Full Text] [Related]
14. Targeted imaging of uPAR expression in vivo with cyclic AE105 variants.
Leth JM; Newcombe EA; Grønnemose AL; Jørgensen JT; Qvist K; Clausen AS; Knudsen LBS; Kjaer A; Kragelund BB; Jørgensen TJD; Ploug M
Sci Rep; 2023 Oct; 13(1):17248. PubMed ID: 37821532
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Urokinase-Type Plasminogen Activator Receptor (uPAR) in Human Diseases With a View to Non-invasive Imaging and Therapeutic Intervention.
Leth JM; Ploug M
Front Cell Dev Biol; 2021; 9():732015. PubMed ID: 34490277
[TBL] [Abstract][Full Text] [Related]
16. Self-assembled chitosan polymer intercalating peptide functionalized gold nanoparticles as nanoprobe for efficient imaging of urokinase plasminogen activator receptor in cancer diagnostics.
Shahdeo D; Kesarwani V; Suhag D; Ahmed J; Alshehri SM; Gandhi S
Carbohydr Polym; 2021 Aug; 266():118138. PubMed ID: 34044952
[TBL] [Abstract][Full Text] [Related]
17. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
[TBL] [Abstract][Full Text] [Related]
18. Improved positron emission tomography imaging of glioblastoma cancer using novel
Loft MD; Sun Y; Liu C; Christensen C; Huang D; Kjaer A; Cheng Z
Amino Acids; 2017 Jun; 49(6):1089-1100. PubMed ID: 28316028
[TBL] [Abstract][Full Text] [Related]
19. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor.
Ploug M; Ellis V; Danø K
Biochemistry; 1994 Aug; 33(30):8991-7. PubMed ID: 8043585
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
